- Home
- DEI vs AKRO Comparison
DEI vs AKRO Comparison
Compare DEI & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEI
- AKRO
- Stock Information
- Founded
- DEI 1971
- AKRO 2017
- Country
- DEI United States
- AKRO United States
- Employees
- DEI N/A
- AKRO N/A
- Industry
- DEI Real Estate Investment Trusts
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- DEI Real Estate
- AKRO Health Care
- Exchange
- DEI Nasdaq
- AKRO Nasdaq
- Market Cap
- DEI 2.4B
- AKRO 2.8B
- IPO Year
- DEI 2006
- AKRO 2019
- Fundamental
- Price
- DEI $14.50
- AKRO $42.39
- Analyst Decision
- DEI Buy
- AKRO Strong Buy
- Analyst Count
- DEI 9
- AKRO 9
- Target Price
- DEI $18.50
- AKRO $76.29
- AVG Volume (30 Days)
- DEI 1.7M
- AKRO 1.1M
- Earning Date
- DEI 05-06-2025
- AKRO 05-16-2025
- Dividend Yield
- DEI 5.24%
- AKRO N/A
- EPS Growth
- DEI N/A
- AKRO N/A
- EPS
- DEI 0.32
- AKRO N/A
- Revenue
- DEI $995,663,000.00
- AKRO N/A
- Revenue This Year
- DEI $0.56
- AKRO N/A
- Revenue Next Year
- DEI N/A
- AKRO N/A
- P/E Ratio
- DEI $45.78
- AKRO N/A
- Revenue Growth
- DEI 1.93
- AKRO N/A
- 52 Week Low
- DEI $12.39
- AKRO $17.86
- 52 Week High
- DEI $20.50
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- DEI 50.81
- AKRO 52.42
- Support Level
- DEI $13.79
- AKRO $41.60
- Resistance Level
- DEI $14.63
- AKRO $46.47
- Average True Range (ATR)
- DEI 0.47
- AKRO 2.05
- MACD
- DEI 0.15
- AKRO 0.37
- Stochastic Oscillator
- DEI 85.36
- AKRO 55.60
About DEI Douglas Emmett Inc.
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. It is an owner and operator of office and multifamily properties located in coastal submarkets in Los Angeles and Honolulu. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments, the office segment and the multifamily segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.